Two 16-week phase 1 trials, one in subjects with obesity and another with T2D, shows significant reductions in body weight and HbA1c, respectively ( 2 without T2D demonstrates mean body weight losses of 6.8%, 13.6%, 16.7%, 18.7%, and 2.0% with 0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg, and placebo, respectively ( 2 treated with survodutide 0.3, 0.9, 1.8, 2.7 mg weekly, 1.2 mg and 1.8 mg twice weekly, compared to semaglutide 1.0 mg weekly or placebo shows mean HbA1c percentage point reductions of 0.9, 1.5, 1.7, 1.6, 1.6, 1.7, 1.5, and 0.2, respectively, as well as mean body weight reductions significantly greater than placebo at all treatment doses, the highest being 8.7% for the 1.8 mg twice a week dose ( 3.5.4 Cotadutide Cotadutide is a GLP-1 and glucagon receptor co-agonist administered subcutaneously once daily
~ AlphaMD Sermorelin is a synthetic peptide that stimulates the bodys natural production of growth hormone
At ~5382 Da, FOXO4-DRI is above the typical renal filtration threshold (~60 kDa for globular proteins, but much lower for linear peptides), suggesting renal clearance may contribute to elimination
The Takeaway Properly used injections are an effective treatment for growth hormone deficiency
